Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jan 26, 2009
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
It is hypothesized that the negative pressure associated with an IVAC is not sufficient to remove BMP-2 from a surgical wound.
BMP-2 is commonly used in open tibia fractures at the time of definitive wound closure, and these wounds are prone to increased swelling and wound complications. The recent observation that IVAC decreases wound edema and increases oxygenation has led to their use in such cases. Used in conjunction, it is entirely possible that the negative pressure exerted by the IVAC can remove BMP-2 from surgical site and therefore decreases the effectiveness of BMP-2. We seek to...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is 18 years or older
- • Subject has tibia fracture requiring treatment with BMP-2
- • Subject to have an Incisional Vacuum Closure (IVAC) Device, placed on the skin directly over the BMP-2 implantation site
- • Subject/guardian able to provide informed consent
- Exclusion Criteria:
- • Subject is less than 18 years old
- • Subject has a wound at fracture/surgical site that cannot be closed
- • Subject/guardian unable to provide informed consent
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbia, Missouri, United States
Patients applied
Trial Officials
Brett D. Crist, MD
Principal Investigator
University of Missouri-Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials